DexCom (DXCM)
(Delayed Data from NSDQ)
$69.46 USD
+0.52 (0.75%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $69.46 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
DexCom, Inc. [DXCM]
Reports for Purchase
Showing records 361 - 380 ( 415 total )
Company: DexCom, Inc.
Industry: Medical - Products
Medical Device-notes from first annual Irvine/San Diago " Bus Tour "This report contains brief updates on the following: ELGX, DXCM, CYTX, GPRO, NUVA, RMD, ALR, MASI, SGNT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
SOLID Q4 - PUSHING HARD ON GEN 4- RAISING PT TO $13.50 - BUY
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: DexCom, Inc.
Industry: Medical - Products
DXCM DexCom reports Q4, acquires SweetSpot; reiterate HOLD, $9.00PT
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
Reports Solid Q4 Financials and Announces Strategic Acquisition of Healthcare IT Company.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
DXCM DexCom unveils 2012 guidance; maintaining HOLD, lowering price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
Preannounced Inline Q4 Product Revenue and Issued Decent 2012 Guidance. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Publication of Data Showing Medical Benefit of CGM Use in T2D an Incremental Positive, But Near-Term Reimbursement Unlikely, In Our View.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Revs Meets Expectations-Per Share Loss-Slightly Higher-Q4 Guidance Lowed
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: DexCom, Inc.
Industry: Medical - Products
DXCM Q3 earnings disappoint, guidance reduced, maintaining HOLD
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
Macro Factors Cause Q3 Miss and Lower Guidance, But DXCM Remains Leader in CGM Market, in our View -- Reiterate OUTPERFORM But Lowering FV to $15.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
DXCM Q3 preview a?? cautious on second half 2011, reducing to HOLD
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
DXCM Q3 preview a?? cautious on second half 2011, reducing to HOLD
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences-Upcoming Events for the Week of October 16
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: DexCom, Inc.
Industry: Medical - Products
The Truffle Shuffle-Diabetes Edition: Investment Implications of Obesity on Diabetes Devices
Provider: FELTL & COMPANY
Analyst: HAYNOR B